Galapagos, a Belgian biotech developing new treatments for inflammatory diseases, raised $275 million by offering 6.55 million shares (76% ADSs and 24% ordinary shares offered to European investors) at $42.05. The company expected to offer 6.03 million shares, upwardly revised from its originally planned 4.72 million shares. Galapagos will list on the NASDAQ under the symbol GLPG. Morgan Stanley, Credit Suisse and Cowen & Company acted as joint bookrunners on the deal.
